Tofersen for SOD1-ALS

Santosh Deemed To Be University10 Jun, 2025Education

Biogen Inc. announced the outcome of the U.S. Food and Drug Administration’s (FDA) has approved a new drug called Tofersen for people with SOD1-ALS. Peripheral and Central Nervous System Drugs Advisory Committee meeting on Tofersen, an investigational product for the treatment of superoxide dismutase 1 (SOD1) Amyotrophic Lateral Sclerosis (ALS). The Committee voted unanimously yes (9 yes to 0 no) on the question, “Is the available evidence sufficient to conclude and reasonably likely to predict clinical benefit of Tofersen for treatment of patients with SOD1-ALS”?